| P50 | author | Nicholas A. Buckley | Q37386383 |
| | Carl R Schneider | Q57327212 |
| | Jonathan Brett | Q82772415 |
| | Benjamin Daniels | Q88599088 |
| P2093 | author name string | Andrew J McLachlan | |
| | Sallie-Anne Pearson | |
| | Atheer Nassir | |
| | Emily A Karanges | |
| P2860 | cites work | Polypharmacy in psychiatric practice in the Canary Islands | Q24791813 |
| | Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? | Q28347008 |
| | The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers | Q31015134 |
| | Association between use of multiple psychoactive medicines and hospitalization for falls: retrospective analysis of a large healthcare claim database | Q33829123 |
| | National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 |
| | Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior | Q35175610 |
| | Validation of a claims-based antipsychotic polypharmacy measure | Q35801221 |
| | Clinicians' reasons for antipsychotic coprescribing. | Q36005087 |
| | Safety and tolerability of antipsychotic polypharmacy | Q36062421 |
| | Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? | Q36739841 |
| | Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice | Q37029622 |
| | Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials | Q37137001 |
| | Interventions to reduce antipsychotic polypharmacy: a systematic review | Q38060312 |
| | Health Care Practitioners' Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults | Q39712942 |
| | The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics | Q39868420 |
| | Trends in Psychotropic Dispensing Among Older Adults with Dementia Living in Long-Term Care Facilities: 2004-2013. | Q40365485 |
| | Psychopharmacology: rational and irrational polypharmacy | Q43463430 |
| | Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans | Q45332374 |
| | Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. | Q46814329 |
| | Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. | Q50552283 |
| | Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? | Q50674716 |
| | Combination antipsychotic therapy in clinical practice. | Q51951314 |
| | Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? | Q57244704 |
| | Antipsychotic polypharmacy: evidence based or eminence based? | Q78336049 |
| | Off-label use of atypical antipsychotics: cause for concern? | Q83744241 |
| | Assigning exposure duration to single prescriptions by use of the waiting time distribution | Q86847735 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Australia | Q408 |
| P304 | page(s) | 2581-2588 | |
| P577 | publication date | 2017-08-16 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study | |
| P478 | volume | 83 | |